Adagrasib + Cetuximab fails to outperform chemo in KRAS G12C mCRC
The phase III KRYSTAL-10 clinical trial found that the combination of adagrasib and cetuximab did not improve survival outcomes compared to standard chemotherapy for patients with KRAS G12C-mutated metastatic colorectal cancer. The results failed to meet primary endpoints, disappointing researchers who had high expectations based on earlier phase I/II data.
Why it matters
This outcome impacts treatment protocols for metastatic colorectal cancer and highlights the challenges of translating early-stage drug trial success into phase III results.
The phase III KRYSTAL-10 trial did not meet its co-primary survival endpoints
The article is a technical report on clinical trial data with no discernible bias.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in